Communiqués Voyageur Pharmaceuticals Ltd. OTC Markets

Actions

VYYR.F

CA92918C1014

Produits pharmaceutiques

Marché Fermé - OTC Markets Autres places de cotation 21:35:25 03/06/2026			Varia. 5j.	Varia. 1 janv.
0,0140 ^USD	0,00%		0,00%	-89,24%

10/06	Voyageur Pharmaceuticals Ltd dépose une demande de permis d'exploration pluriannuelle pour l'échantillonnage en vrac et l'étude de faisabilité du projet de barytine Frances Creek	CI
24/04	Voyageur Pharmaceuticals Ltd. publie ses résultats pour le premier trimestre clos le 28 février 2026	CI

Communiqués

10/06	Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project	AQ
06/06	Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption	AQ
17/04	Voyageur Announces Shares for Debt Settlement and Stock Option Repricing	AQ
16/03	Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects	AQ
05/03	Voyageur Pharmaceuticals : Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant	PU
04/03	Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt	AQ
23/02	Voyageur Pharmaceuticals Announces Collaboration with Bayer	AQ
12/01	Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology	AQ
07/11	Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion	AQ
29/10/25	Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX	AQ
23/10/25	Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion	AQ
25/08/25	Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform	AQ
21/08/25	Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics	AQ
19/08/25	Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million	AQ
18/08/25	Voyageur Advances Frances Creek Barite Project with VAST Engagement for Bulk Sample Permit	AQ
14/07/25	Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants	AQ
24/06/25	Voyageur Pharmaceuticals : Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion	PU
23/06/25	Voyageur and Altillion Forge Landmark Alliance to Establish North America's First Vertically Integrated Iodine Drug Supply Chain	AQ
04/06/25	Voyageur Enters Revenue Stage with First Commercial Sale of Barium Contrast Agents	AQ
12/05/25	Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President	AQ
01/05/25	Voyageur Pharmaceuticals Announces Changes to Board of Directors and DSU Grant	AQ
23/04/25	Voyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study Results	AQ
01/04/25	Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch	AQ
04/03/25	Voyageur Pharmaceuticals Advances Frances Creek Project, Paving the Way for a Secure, Vertically Integrated Barium Contrast Product Line	AQ
03/03/25	Voyageur Clarifies Terms of Previously Announced Agreement	NE